FI107926B - Sytokiinin synteesiä inhiboiva faktori, sen antagonistit ja näiden käyttömenetelmät - Google Patents

Sytokiinin synteesiä inhiboiva faktori, sen antagonistit ja näiden käyttömenetelmät Download PDF

Info

Publication number
FI107926B
FI107926B FI916126A FI916126A FI107926B FI 107926 B FI107926 B FI 107926B FI 916126 A FI916126 A FI 916126A FI 916126 A FI916126 A FI 916126A FI 107926 B FI107926 B FI 107926B
Authority
FI
Finland
Prior art keywords
sequence
amino acid
factor
polypeptide
nucleic acid
Prior art date
Application number
FI916126A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI916126A0 (fi
Inventor
Martha W Bond
Kevin W Moore
Paulo J M Vieira
Timothy R Mosmann
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI916126A0 publication Critical patent/FI916126A0/fi
Application granted granted Critical
Publication of FI107926B publication Critical patent/FI107926B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI916126A 1989-06-28 1991-12-27 Sytokiinin synteesiä inhiboiva faktori, sen antagonistit ja näiden käyttömenetelmät FI107926B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US37266789A 1989-06-28 1989-06-28
US37266789 1989-06-28
US45395189A 1989-12-20 1989-12-20
US45395189 1989-12-20
PCT/US1990/003554 WO1991000349A1 (en) 1989-06-28 1990-06-28 Cytokine synthesis inhibitory factor, antagonists thereof, and methods of using same
US9003554 1990-06-28

Publications (2)

Publication Number Publication Date
FI916126A0 FI916126A0 (fi) 1991-12-27
FI107926B true FI107926B (fi) 2001-10-31

Family

ID=27005854

Family Applications (1)

Application Number Title Priority Date Filing Date
FI916126A FI107926B (fi) 1989-06-28 1991-12-27 Sytokiinin synteesiä inhiboiva faktori, sen antagonistit ja näiden käyttömenetelmät

Country Status (22)

Country Link
EP (2) EP0405980A1 (pt)
JP (1) JP2813063B2 (pt)
KR (1) KR0183035B1 (pt)
CN (3) CN1051393A (pt)
AT (1) ATE180833T1 (pt)
AU (1) AU635058B2 (pt)
CA (1) CA2062763C (pt)
CS (1) CS414591A3 (pt)
DE (1) DE69033143T2 (pt)
DK (1) DK0567450T3 (pt)
ES (1) ES2132068T3 (pt)
FI (1) FI107926B (pt)
GR (1) GR3030404T3 (pt)
HK (3) HK1008834A1 (pt)
HU (1) HU216310B (pt)
IL (1) IL94878A (pt)
NO (1) NO301718B1 (pt)
NZ (1) NZ234291A (pt)
PT (1) PT94514B (pt)
SG (1) SG52282A1 (pt)
TW (1) TW218383B (pt)
WO (1) WO1991000349A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
US6106823A (en) 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
ES2068705T3 (es) * 1991-01-16 1995-04-16 Schering Corp Tratamiento de la enfermedad neoplastica con interleuquina-10.
DE69203443T2 (de) * 1991-01-16 1995-12-07 Schering Corp Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
ES2138976T3 (es) * 1991-08-06 2000-02-01 Schering Corp Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos.
ZA931489B (en) * 1992-03-04 1993-10-28 Schering Corp Use of interleuken-10 to suppress graft-vs-host disease
US6277635B1 (en) 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
US6884410B1 (en) 1992-03-04 2005-04-26 Schering Corporation Methods for modulating antigen-specific immune responses
AU3801193A (en) * 1992-03-20 1993-10-21 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
HU220103B (hu) * 1992-08-20 2001-10-28 Schering-Plough Corp. IL-10 új alkalmazása
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
JPH08501549A (ja) * 1992-09-18 1996-02-20 スケアリング コーポレイション Ｈｉｖ感染された患者におけるｔヘルパー細胞の免疫担当能力の回復
ES2131122T3 (es) * 1992-10-01 1999-07-16 Schering Corp Uso de il-10 para prevenir la diabetes mellitus dependiente de insulina.
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
CA2155109A1 (en) * 1993-02-01 1994-08-18 Daniel Abramowicz Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
PL312718A1 (en) * 1993-07-26 1996-05-13 Schering Corp Competitors and opponents of human interleukine-10
US5650060A (en) * 1994-01-28 1997-07-22 Minnesota Mining And Manufacturing Company Ionically conductive agent, system for cathodic protection of galvanically active metals, and method and apparatus for using same
US6159937A (en) 1994-07-05 2000-12-12 Steeno Research Group A/S Immunomodulators
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
CN101307106B (zh) * 1995-12-13 2013-06-12 儿童医学中心公司 内皮细胞增殖抑制剂及其应用方法
AU4385696A (en) * 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues
CN1216470A (zh) * 1996-04-17 1999-05-12 帕特里克·T·普伦德加斯特 脱氢表雄酮组合治疗方法
AU722570B2 (en) * 1996-09-06 2000-08-03 Schering Corporation Method for lowering cholesterol levels
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US6465176B1 (en) * 1998-10-02 2002-10-15 Message Pharmaceuticals, Inc. Method for identifying compounds RNA/RNA binding protein interactions
AU5047600A (en) * 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
AU8729101A (en) 2000-03-31 2001-10-15 Idec Pharma Corp Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma
EP2582386A2 (en) 2010-06-16 2013-04-24 Allergan, Inc. Il-10 and methods of treating ocular and other diseases
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US11596670B2 (en) 2017-03-30 2023-03-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB202003428D0 (en) * 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
IE62650B1 (en) * 1989-08-04 1995-02-22 David & Sons Ltd Dispensing apparatus
ZA9010188B (en) * 1989-12-20 1991-08-28 Schering Corp Bcrf1 proteins as inhibitors of interferon-gamma

Also Published As

Publication number Publication date
CN1051393A (zh) 1991-05-15
KR920701437A (ko) 1992-08-11
CS414591A3 (en) 1992-12-16
SG52282A1 (en) 1998-09-28
KR0183035B1 (ko) 1999-04-01
DE69033143T2 (de) 1999-10-21
DK0567450T3 (da) 1999-12-13
AU6077090A (en) 1991-01-17
JPH04502560A (ja) 1992-05-14
PT94514B (pt) 1998-02-27
TW218383B (pt) 1994-01-01
EP0405980A1 (en) 1991-01-02
GR3030404T3 (en) 1999-09-30
NO915115D0 (no) 1991-12-27
IL94878A0 (en) 1991-04-15
EP0567450B1 (en) 1999-06-02
ATE180833T1 (de) 1999-06-15
AU635058B2 (en) 1993-03-11
NO301718B1 (no) 1997-12-01
NZ234291A (en) 1992-11-25
PT94514A (pt) 1991-04-18
HK1040493B (zh) 2005-12-16
CN1317343A (zh) 2001-10-17
HU906705D0 (en) 1992-03-30
JP2813063B2 (ja) 1998-10-22
WO1991000349A1 (en) 1991-01-10
CA2062763A1 (en) 1990-12-29
DE69033143D1 (de) 1999-07-08
HK1040531B (zh) 2008-01-11
NO915115L (no) 1992-02-26
FI916126A0 (fi) 1991-12-27
HU216310B (hu) 1999-06-28
CN1318589C (zh) 2007-05-30
HK1040493A1 (en) 2002-06-14
HUT61048A (en) 1992-11-30
HK1040531A1 (en) 2002-06-14
ES2132068T3 (es) 1999-08-16
EP0567450A1 (en) 1993-11-03
CN1198642C (zh) 2005-04-27
CN1317569A (zh) 2001-10-17
HK1008834A1 (en) 1999-05-21
IL94878A (en) 2003-01-12
CA2062763C (en) 2010-01-05

Similar Documents

Publication Publication Date Title
FI107926B (fi) Sytokiinin synteesiä inhiboiva faktori, sen antagonistit ja näiden käyttömenetelmät
US5231012A (en) Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US6217857B1 (en) Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
CA2090126C (en) Methods for the production of proteins with a desired function
KR930008112B1 (ko) 사람 인터루킨-4에 대한 모노클로날 항체 및 이를 생성하는 하이브리도마
US20060228329A1 (en) Homogeneous preparations of IL-31
JPH07508179A (ja) ヒトインターロイキン−１３
AU8228891A (en) Surface complexed lymphotoxin
Favre et al. Epitope mapping of recombinant human gamma interferon using monoclonal antibodies
EP0491878B1 (en) Compositions for the inhibition of protein hormone formation and uses thereof
EP0851030A1 (en) PROTEIN SPECIFIC TO HUMAN Th2, GENE (B19) ENCODING THE SAME, AND TRANSFORMANT, RECOMBINANT VECTOR AND MONOCLONAL ANTIBODY RELATING THERETO
US6207154B1 (en) Methods of treatment using antagonists of cytokine synthesis inhibitory factor
US5434247A (en) Peptides for inducing monocyte cytotoxicity in diagnostics
JPH1070986A (ja) ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体
IE902346L (en) Cytokine synthesis inhibitory factor
WO2008141511A1 (fr) ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION
JP2779621B2 (ja) モノクローナル抗体，ハイブリドーマ，それらの製造法およびそれらの用途
JP2004533834A (ja) ヒトタキキニン関連スプライシング変異体およびその組成物
EP0417196A1 (en) Immunogenic human interleukin-3 peptide and monoclonal antibodies thereto
JP2000186099A (ja) モノクロ―ナル抗体